Relationship between serum miR-141-3p expression and the efficacy and prognosis of platinum based chemotherapy in patients with non-small cell lung cancer
10.3969/j.issn.1673-4130.2025.20.004
- VernacularTitle:非小细胞肺癌患者血清miR-141-3p表达与含铂化疗方案疗效及预后的关系
- Author:
Zhongyan LI
1
;
Yaohua CHEN
Author Information
1. 四川省达州市中心医院呼吸内科,四川达州 635000
- Keywords:
non-small cell lung cancer;
microRNA-141-3p;
platinum based chemotherapy;
efficacy;
prognosis
- From:
International Journal of Laboratory Medicine
2025;46(20):2452-2457,2463
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the relationship between serum microRNA(miR)-141-3p expression and the efficacy and prognosis of platinum based chemotherapy regimens in patients with non-small cell lung cancer(NSCLC).Methods A total of 154 NSCLC patients who received platinum based chemotherapy be-tween January 2018 and May 2021 were enrolled(NSCLC group),along with 78 healthy volunteers during the same period(control group)for comparison and analysis.Serum miR-141-3p expression was measured using real-time quantitative PCR,and its relationship with clinicopathological characteristics was analyzed.NSCLC patients were divided into an ineffective group and an effective group based on chemotherapy response,and further categorized into high miR-141-3p expression and low miR-141-3p expression groups based on the aver-age value of miR-141-3p expression.The relationship between miR-141-3p expression and the ineffectiveness of platinum based chemotherapy regimens and mortality in NSCLC patients was analyzed.The predictive effi-cacy of serum miR-141-3p expression for the ineffectiveness of platinum based chemotherapy regimens in NSCLC patients was analyzed by receiver operating characteristic curve.Kaplan Meier method was used to plot survival curves of NSCLC patients with different miR-141-3p expression levels.Results Serum miR-141-3p expression was significantly lower in NSCLC group compared to the control group(P＜0.05).Patients with largest tumor size≥5 cm,poor differentiation,TNM stage Ⅲ-Ⅳ,lymph node metastasis,or distant me-tastasis showed lower serum miR-141-3p expression compared to those with largest tumor size＜5 cm,mod-erate-to-high differentiation,TNM stage Ⅱ,and no lymph node or distant metastasis(P＜0.05).Among 154 NSCLC patients,the inefficacy rate of platinum based chemotherapy was 59.74％(80/154).The expression of miR-141-3p in the ineffective group was lower than that in the effective group(P＜0.05).Multivariate Logis-tic regression showed that high miR-141-3p expression was identified as an independent protective factor of the inefficacy of platinum based chemotherapy(P＜0.05).The area under the curve for predicting the ineffi-cacy of platinum based chemotherapy using serum miR-141-3p expression was 0.816,with sensitivity of 77.50％and specificity of 68.92％.The 3-year survival rate for the 154 NSCLC patients was 55.19％(85/154).Patients with high miR-141-3p expression had a significantly higher 3-year survival rate compared to those with low miR-141-3p expression(P＜0.05).Cox regression showed that high miR-141-3p expression was also identified as an independent protective factor of the mortality in NSCLC patients(P＜0.05).Conclusion The low expression of miR-141-3p in the serum of NSCLC patients is closely related to pathologi-cal features,the efficacy and prognosis of platinum based chemotherapy regimens,and may become an auxiliary evalu-ation indicator for the efficacy and prognosis of platinum based chemotherapy regimens in NSCLC patients.
